A Study of Ibrutinib (PCI-32765) in Chinese Participants With Relapse or Refractory Waldenstrom's Macroglobulinemia (WM)
Clinical trial NCT04042376 · COMPLETED
Trial details
- NCT number
- NCT04042376
- Sponsor
- Janssen Research & Development, LLC
- Status
- COMPLETED
- Phase
- Phase 4
- Study type
- INTERVENTIONAL
- Start date
- 2019-12-18
- Primary completion
- 2024-03-19
- Enrollment
- 17
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.